Bing

SEARCH HISTORY

Repros Therapeutics (NASDAQ:RPRX)‘s stock had its “buy” rating restated by investment analysts at Laidlaw in a note issued to investors on Tuesday, Analyst Ratings Network.com reports. Repros Therapeutics (NASDAQ:RPRX) traded up 2.74% …
Ticker Report · 2 hours ago
Repros Therapeutics
Repros Therapeutics (NASDAQ:RPRX) is a company whose shares are active ... or 74.1% below the average consensus analyst price target of $29.25. The stock should hit resistance at its 200-day moving average (MA) of $8.28, as well as support at its 50 ...
Financial News Network Online · ByAdrienne Chilton · 5 hours ago
Repros Therapeutics
Repros Therapeutics Inc. (RPRX) saw a big move last session, as the company’s shares fell more than 10% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent …
Yahoo Finance · 9/18/2014
More from Bing News
NEW YORK (TheStreet) -- Shares of Repros Therapeutics (RPRX) plummeted to a 52-week low of $8.88 on Thursday after an FDA panel put up a roadblock for the company's low-testosterone drug Androxal. The panel expressed concern that doctors were …
The Street · 4/1/1997
Repros Therapeutics Inc (NASDAQ:RPRX) was in 15 hedge funds’ portfolio at the end of the first quarter of 2013. RPRX shareholders have witnessed an increase in support from the world’s most elite money managers recently. There were 12 hedge …
INSIDER MONKEY · 6/6/2013
Repros Therapeutics (NASDAQ:RPRX)‘s stock had its “hold” rating restated by Zacks in a research report issued to clients and investors on Friday. Zacks’ analyst wrote, “Zonagen Inc. is a biopharmaceutical company engaged in the development of ...
wkrb13.com · 5/3/2015
Repros Therapeutics Inc. ( RPRX) saw a big move last session, as the company's shares fell more than 10% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent …
NASDAQ · 9/18/2014
Repros Therapeutics (NASDAQ:RPRX)‘s stock had its “hold” rating reiterated by Zacks in a research note issued to investors on Friday. Zacks’ analyst wrote, “Zonagen Inc. is a biopharmaceutical company engaged in the development of products for ...
sleekmoney.com · 5/2/2015
Repros Therapeutics Inc. (Nasdaq: RPRX) 7.1% HIGHER; announced it has initiated two Phase 2B efficacy studies of Proellex® in the treatment of uterine fibroids in women that experience heavy vaginal bleeding as a result of these benign tumors. The two ...
StreetInsider · 12/29/2014
Repros Therapeutics Inc. (NASDAQ:RPRX) yesterday filed the NDA for its late stage ... I stand with my bullish sentiment on the stock and expect that Androxal may finally be able to reach the market in the near future. However, if there are any delays ...
Seeking Alpha · 2/3/2015